Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric ...
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on ...
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Travere Therapeutics teilte am Mittwoch mit, dass das Unternehmen vom US-Patent- und Markenamt eine Mitteilung über die ...
Am 21. September 2026 haben Travere Therapeutics, Inc. und Eric Dube, Ph.D., einvernehmlich den Zeitplan und die Bedingungen ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Finnmark er ikke som resten av landet. Stein-Tore Lund tror derfor at 2026 kan bli det beste året for bilbutikken han styrer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results